Ophthalmic medical device company Implandata Ophthalmic Products GmbH (Implandata) announced that study enrolment of its international ARGOS-SC01 clinical study was completed with the inclusion of the 24th study patient.
NLS Pharmaceutics Ltd (NLS), a Swiss biotech firm focusing on the development of novel treatments for Attention-Deficit/Hyperactivity Disorder (ADHD) and other cognitive disorders and impairments, today announced the closing of the merger of NLS Pharma Lt
Spectrum Pharmaceuticals, Inc. (NASDAQ-GS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, today completed the sale of its portfolio of seven FDA-approved hematology/oncology products to Acrotech Biopharma L.L.C., a s